Trial
NCT03912337
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
Novartis
Condition
Migraine
Intervention
Placebo
Why stopped
Terminated \[Study would not complete enrollment target until 2026 with results available in 2027. The information will not be useful at that time.\]
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-20